Cancer clinical trials in the region Normandie

239 currently recruiting clinical trials
Region Normandie

Phase 3 Head and neck cancer #NCT04892173
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Surgery Chemotherapy Radiotherapy Radiochemotherapy
15 recruiting sites
Johnson & Johnson Enterprise Innovation Inc.
Phase 3 Head and neck cancer #NCT07264075 #2025-522996-27-00
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Targeted therapy
6 recruiting sites
Groupe Oncologie Radiothérapie Tête et Cou (GORTEC)
Phase 3 Head and neck cancer #NCT06525220 #2023-510323-30-00
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
14 recruiting sites
Merus
Phase 3 Lymphoma #NCT06717347 #2024-515566-13-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
14 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Lung cancer #NCT06868277 #2024-517780-24-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR ROS-1
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
11 recruiting sites
AstraZeneca
Phase 3 Stomach and esophageal cancer #NCT06764875 #2024-512583-57-00
Required histologic types
Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)
6 recruiting sites
AstraZeneca
Phase 3 Sarcoma and GIST #NCT04307277 #2024-515384-62-00
Required histologic types
Soft tissue sarcoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Required sarcoma grades
Grade 1 Grade 2 Grade 3
20 recruiting sites
Institut Claudius Regaud
Phase 3 Colon cancer Rectal cancer #NCT02885753
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
84 recruiting sites
Fédération Francophone de Cancérologie Digestive
Phase 3 Acute leukemia #NCT04307576 #2022-501050-11-01
Required histologic types
Acute lymphoblastic leukemia (ALL)
Required histologic sub types
T-cell (T-ALL) B-cell (B-ALL)
Required genetic anomalies
MYC
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
28 recruiting sites
Karolinska University Hospital
Phase 3 Lung cancer #NCT04790253
Required histologic types
SCLC (Small Cell Lung Cancer)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
16 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer